Arizona State Retirement System Acquires 441 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Arizona State Retirement System raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) by 2.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,163 shares of the biopharmaceutical company’s stock after purchasing an additional 441 shares during the period. Arizona State Retirement System’s holdings in Ultragenyx Pharmaceutical were worth $719,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RARE. Vanguard Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,161,866 shares of the biopharmaceutical company’s stock worth $255,163,000 after buying an additional 27,722 shares during the period. BlackRock Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 4.0% in the second quarter. BlackRock Inc. now owns 5,067,027 shares of the biopharmaceutical company’s stock worth $233,742,000 after buying an additional 193,671 shares during the period. Wellington Management Group LLP raised its holdings in shares of Ultragenyx Pharmaceutical by 17.1% in the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company’s stock worth $244,747,000 after buying an additional 492,842 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 3.1% in the first quarter. Clearbridge Investments LLC now owns 2,863,921 shares of the biopharmaceutical company’s stock worth $207,978,000 after buying an additional 85,062 shares during the period. Finally, Sands Capital Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth approximately $123,335,000. 96.37% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $44.71 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98. The business has a fifty day moving average price of $45.11 and a 200-day moving average price of $39.98.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RARE shares. Robert W. Baird increased their price target on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Piper Sandler dropped their price objective on Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 25th. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $114.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, January 19th. Finally, StockNews.com raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, December 8th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $90.60.

Read Our Latest Stock Report on RARE

About Ultragenyx Pharmaceutical

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Featured Stories

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.